Particularly, the identification of the HSP90AA1 gene as a promising therapeutic target offers potential avenues for LC prevention and intervention, with the prospect of enhancing treatment efficacy. This evidence concerns the gene HSP90AA1 and laryngotracheoesophageal cleft.